780758-10-3

Nimotuzumab(Taixinsheng) is a biologically targeted drug that acts on the epidermal growth factor receptor (EGFR) on the surface of tumor cells, inhibiting the proliferation and differentiation of tumor cells. It has the advantages of low reaction and good safety.
Suitable for head and neck tumors, gliomas, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, non-small cell lung cancer and other solid tumors.

Nimotuzumab, as the first humanized monoclonal antibody in my country, can competitively bind to EGFR and block its conduction pathway, thereby inhibiting tumor cell proliferation and tumor angiogenesis, thereby enhancing the efficacy of radiotherapy and chemotherapy.

EGFR